Carisma Therapeutics Inc (NASDAQ:CARM)
| 2.46 Delayed Data As of Dec 01 |  +0.06 / +2.50%Today’s Change | 2.18 Today|||52-Week Range 13.00 | -79.82% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $99.3M |
Company Description
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in 2016 and is headquartered in Philadelphia, PA.
Contact Information
Carisma Therapeutics, Inc. 3675 Market Street Philadelphia Pennsylvania 19104 |
Employees
Shareholders
| Other institutional | 9.98% |
| Mutual fund holders | 9.17% |
| Individual stakeholders | -- |
Top Executives
| Steven Kelly | President, Chief Executive Officer & Director |
| Richard Steven Morris | CFO, Treasurer & Chief Compliance Officer |
| Michael Klichinsky | Chief Scientific Officer |
| Daniel J. Cushing | Chief Technology & Development Officer |
| Tom Wilton | Chief Business Officer |
